News

The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke on what he is looking forward to at the 2021 International Congress on the Future of Neurology.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 13, 2021.

The chief medical officer of Wave Life Sciences, Michael Panzara, MD, MPH, discussed the potential of an investigational new treatment, WVE-004, for patients with C9orf72-associated ALS and FTD.

The professor of neurology at Mayo Clinic College of Medicine discussed the 3 currently FDA-approved agents for NMOSD and other agents currently within the clinical pipeline.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Mitchell S.V. Elkind, MD, MS, MPhil.

Surgery for eligible patients was shown to increase rates of seizure freedom, as well as improve developmental levels, among those with TSC.

After years of only off-label, wake-promoting therapies available for use, the FDA has approved the first treatment for idiopathic hypersomnia, JZP-258 (Xywav; Jazz).

The director of the MedStar Georgetown Headache Center discussed the upcoming International Congress on the Future of Neurology and what attendees can expect to hear from experts in migraine.

The association of increased EVT rates was noted with the initiation of online training and EMS dissemination of the policy in September 2018, 2 months in advance of formal implementation of prehospital protocol.

Michael Panzara, MD, MPH, chief medical officer of Wave Life Sciences, spoke on the FOCUS-C9 study, which recently began dosing of an investigational treatment, WVE-004, for patients with ALS and FTD.

The autologous, expanded Treg cell therapy was found safe and tolerable in a phase 1 study of 3 patients with ALS.

A narrative review was conducted to evaluate the relationship between gender-affirming hormone therapy and headache to advance care and improve resources for the transgender and gender-diverse population.

Following the commencement of a study exploring WVE-004, an investigational treatment for C9-ALS and C9-FTD, the director of the Sean M. Healey & AMG Center for ALS discussed the clinical implications and the treatment’s potential.

Two unblinded interim analyses by the Data Monitoring Committee are planned to assess the futility of reldesemtiv, with the first occurring 12 weeks after one-third of the sample size is randomized.

The professor of neurology at the Mayo Clinic College of Medicine detailed the strides made in recognizing NMOSD as its own disease, along with specific biomarkers that identify it.

The professor of health science at the Medical University of South Carolina discussed robust results from the phase 3 ADMET 2 study evaluating methylphenidate to treat apathy in Alzheimer disease.

Adverse reactions were consistent with the known side effect profile of sodium oxybate and were generally mild or moderate in new data from the REST-ON trial (NCT02720744).

Lumosa Therapeutics announced that phase 2b of LT3001 met its primary safety end point, with data indicating its potential for clinical benefit.

The director of the Sean M. Healey & AMG Center for ALS outlined the trial, which will evaluate ideal dose level and frequency of the investigational treatment for patients with C9-ALS and C9-FTD.

The investigational agent NOE-105 has previously been found safe for treating adults with Tourette syndrome at 30-mg daily doses.

The assistant professor of neurology at Harvard Medical School discussed related areas of research regarding cranial neuralgias and the optimal time to proceed with surgery.

Investigators obtained a molecular diagnostic yield of 39% in 66 sequential, unselected individuals with diverse presentations of rare neurogenetic disorders when using a model that integrates additional assays.

In addition to the uplifted phase 1 study, Novartis also initiated the phase 3 STEER study, which will evaluate OAV-101 in treatment-naive patients with SMA type 2 aged between 2 and 18 years old.

The executive director of Banner Alzheimer’s Institute discussed the approval of aducanumab and the potential to address unmet needs and gaps in care for patients with Alzheimer disease.

A lateralization effect was observed for patients with left temporal lobe epilepsy, as their BrainAGE values more closely resembled control group values following surgery.

Developed by Wave Life Sciences, the trial of the investigational treatment, WVE-004, seeks to identify ideal dose level and frequency in patients with C9orf72-associated amyotrophic lateral sclerosis and FTD.

The approval of aducanumab and other advancements in Alzheimer disease diagnosis remain at the forefront of discussion; Eric Reiman, MD, spoke on the state of diagnosis and those ongoing conversations.

Here's what is coming soon to NeurologyLive.